Adial Pharmaceuticals
ADIL
10 hedge funds and large institutions have $1.11M invested in Adial Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 2 closing their positions.
36% more capital invested
Capital invested by funds: $817K → $1.11M (+$298K)
0% more funds holding
Funds holding: 10 → 10 (0)
0% less ownership
Funds ownership: 0.01% → 0.01% (-0%)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$217K |
| 2 |
Renaissance Technologies
New York
|
+$60.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$4K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.71K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Vanguard Group
Malvern,
Pennsylvania
| $393K | – | – | – |
|
2
BlackRock
New York
| $286K | – | – | – |
|
|
3
Bank of America
Charlotte,
North Carolina
| $209K | +$217K | +240 | New |
|
4
Geode Capital Management
Boston,
Massachusetts
| $108K | – | – | – |
|
|
5
Renaissance Technologies
New York
| $58K | +$60.5K | +67 | New |
|
6
Brown Advisory
Baltimore,
Maryland
| $36K | – | – | – |
|
7
Commonwealth Equity Services
Waltham,
Massachusetts
| $14K | – | – | – |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| $9K | -$2.71K | -3 | -23% |
|
9
Morgan Stanley
New York
| $1K | – | – | – |
|
10
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
11
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$18K | -22 | Closed |
|
|
12
Victory Capital Management
San Antonio,
Texas
| – | -$4K | -5 | Closed |
|
ADIL Hedge Fund Activity: Q2 2020 in Review
10 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2020, worth a combined $1.11M — up 36% from $817K a quarter earlier.
Fund positioning in ADIL was balanced in Q2 2020: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $217K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $18K sold.
- 10 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $1.11M of Adial Pharmaceuticals stock for Q2 2020, up 36% quarter-over-quarter.
- 2 funds opened new Adial Pharmaceuticals positions in Q2 2020 and 2 closed out, a net change of 0 holders.
- The largest Adial Pharmaceuticals buyer in Q2 2020 was Bank of America, an estimated $217K added.
- The largest Adial Pharmaceuticals seller in Q2 2020 was Susquehanna International Group, an estimated $18K sold.
Based on aggregated 13F filings for Q2 2020.